On September 11, 2026, Opus Genetics, Inc. filed a Current Report on Form 8-K to amend a data presentation previously issued on September 9, 2026. The company disclosed that a revised version of the presentation, furnished as Exhibit 99.1, corrects an immaterial error in the translation of logMAR visual acuity into ETDRS letters. This correction impacts the depiction of mean best-corrected visual acuity from baseline through 3 months in Cohort 1 of the ongoing Phase 1/2 clinical trial for OPGx-BEST1.
The filing provides the specific three-month change from baseline for each participant in the low-dose cohort. These changes are as follows: participant 101-101 saw a 12-letter improvement in the treated eye and a 4-letter improvement in the fellow eye; participant 101-104 experienced a 1-letter improvement in the treated eye and a 7-letter loss in the fellow eye; participant 102-101 had a 10-letter loss in the treated eye and an 8-letter loss in the fellow eye; participant 102-102 saw a 2-letter gain in the treated eye and a 5-letter loss in the fellow eye; and participant 101-106 had a 6-letter gain in the treated eye and a 2-letter gain in the fellow eye.
In addition to the visual acuity data correction, the revised presentation includes high-resolution images of microperimetry grids for baseline and 3 months for each participant. The filing notes that individual loci data is available for the three participants in these images.
